Ascendis Pharma vs Charles River Laboratories International

Ascendis Pharma (ASND), health care, and Charles River Laboratories International (CRL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Ascendis Pharma is worth $17.8B on the stock market and Charles River Laboratories International $15.9B: Ascendis Pharma is valued at 12% more. Ascendis Pharma trades at 17.9 times earnings and Charles River Laboratories International at 365; operating margins in their latest fiscal years were -18.9% and 0.63%. Over the past year Ascendis Pharma's share price has moved +25.1% and Charles River Laboratories International's +106%.

Key facts

Ascendis Pharma market value
$17.8B
Charles River Laboratories International market value
$15.9B
Ascendis Pharma P/E
17.9
Charles River Laboratories International P/E
365
Ascendis Pharma revenue
$799MFY to 2025-12-31
Charles River Laboratories International revenue
$4BFY to 2025-12-27
Superinvestors holding both
0

Market values as of .

Ascendis Pharma vs Charles River Laboratories International: every measure side by side
Measure Ascendis Pharma Charles River Laboratories International
SectorHealth CareHealth Care
Country Denmark United States
Fiscal year ends2025-12-312025-12-27
Size
Market cap$17.8Bhigher$15.9Blower
Revenue$799Mlower$4Bhigher
Earnings-$253Mlower-$144.3Mhigher
Employees1,189lower18,300higher
Total assets$1.4Blower$7.1Bhigher
Valuation
P/E17.9lower365higher
P/S22.3higher4.0lower
P/B—4.9
Dividend yield—0.00%
Profitability
Operating margin-18.9%lower0.63%higher
Balance sheet
Net assets-$180.7Mlower$3.2Bhigher
Total liabilities$1.6Blower$3.9Bhigher
Total debt$799.1Mlower$2.1Bhigher
Cash on hand$683.5Mhigher$213.8Mlower
Price change
Today-0.20%higher-1.00%lower
1 year+25.1%lower+106%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Ascendis Pharma only (2)

Charles River Laboratories International only (7)

Percentages are each holding's share of that investor's reported portfolio. Who owns ASND · Who owns CRL

Further comparisons

Learn

Questions and answers

Which is bigger, Ascendis Pharma or Charles River Laboratories International?

By market value, Ascendis Pharma is the larger: $17.8B against $15.9B for Charles River Laboratories International. By revenue in its latest fiscal year, Charles River Laboratories International is the larger: $4B against $799M for Ascendis Pharma.

Which has the higher P/E ratio?

Charles River Laboratories International: 365, against 17.9 for Ascendis Pharma. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Charles River Laboratories International: 0.63%, against -18.9% for Ascendis Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Charles River Laboratories International: $2.1B, against $799.1M for Ascendis Pharma. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Ascendis Pharma and Charles River Laboratories International?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Ascendis Pharma and 7 hold Charles River Laboratories International.

Cite this page

Funkfolio, “Ascendis Pharma vs Charles River Laboratories International”, data as of 18 November 2026. https://funkfolio.com/compare/asnd-vs-crl

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.